Logo image of BIOS

BIOPLUS ACQUISITION CORP-A (BIOS) Stock Fundamental Analysis

NASDAQ:BIOS - Nasdaq - KYG112171171 - Common Stock - Currency: USD

10.795  -0.01 (-0.05%)

After market: 10.79 -0.01 (-0.05%)

Fundamental Rating

1

BIOS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. BIOS has a bad profitability rating. Also its financial health evaluation is rather negative. BIOS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BIOS had positive earnings in the past year.
In the past year BIOS has reported a negative cash flow from operations.
BIOS Yearly Net Income VS EBIT VS OCF VS FCFBIOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2020 2021 2022 0 -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA 4.18%
ROE 4.75%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOS Yearly ROA, ROE, ROICBIOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2020 2021 2022 0 500 1K 1.5K 2K 2.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOS Yearly Profit, Operating, Gross MarginsBIOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2020 2021 2022 0 20 -20

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, BIOS has more shares outstanding
BIOS has a better debt/assets ratio than last year.
BIOS Yearly Shares OutstandingBIOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2021 2022 20M 40M 60M 80M 100M
BIOS Yearly Total Debt VS Total AssetsBIOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2021 2022 200M 400M 600M

2.2 Solvency

BIOS has an Altman-Z score of 7.24. This indicates that BIOS is financially healthy and has little risk of bankruptcy at the moment.
A Debt/Equity ratio of 0.04 indicates that BIOS is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 7.24
ROIC/WACCN/A
WACCN/A
BIOS Yearly LT Debt VS Equity VS FCFBIOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2021 2022 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 0.10 indicates that BIOS may have some problems paying its short term obligations.
A Quick Ratio of 0.10 indicates that BIOS may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
BIOS Yearly Current Assets VS Current LiabilitesBIOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2021 2022 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1103.65% over the past year.
EPS 1Y (TTM)1103.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOS Yearly Revenue VS EstimatesBIOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 200M 400M 600M 800M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 53.97, the valuation of BIOS can be described as expensive.
When comparing the Price/Earnings ratio of BIOS to the average of the S&P500 Index (26.03), we can say BIOS is valued expensively.
Industry RankSector Rank
PE 53.97
Fwd PE N/A
BIOS Price Earnings VS Forward Price EarningsBIOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOS Per share dataBIOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOPLUS ACQUISITION CORP-A

NASDAQ:BIOS (10/6/2023, 8:18:10 PM)

After market: 10.79 -0.01 (-0.05%)

10.795

-0.01 (-0.05%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.55%
Inst Owner Change0%
Ins Owners9.13%
Ins Owner Change0%
Market Cap209.10M
Analysts100
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 53.97
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)0.2
EY1.85%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS6.29
TBVpS6.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.18%
ROE 4.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z 7.24
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1103.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-205.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.39%
OCF growth 3YN/A
OCF growth 5YN/A